CETP inhibitors derived from benzoxazole arylamides

US8445480B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Julianne A. Hunt · Scotch Plains, US
• Ramzi F. Sweis · Vernon Hills, US
• Dooseop Kim · Scotch Plains, US
• Florida Kallashi · Yonkers, US
• Peter J. Sinclair · Highland Park, US

Key dates

• Filing date: Jun 16, 2008
• Grant date: May 21, 2013
• Expiry date: Nov 4, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds having the structure of Formula I1 including pharmaceutically acceptable salts of the compounds, are potent CETP (cholesterol ester transfer protein) inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis Atherosclerosis and its clinical consequences, coronary heart disease (CHD), stroke and penpheral vascular disease, represent a truly enormous burden to the health care systems of the industrialized world In formula I, A-B is an arylamide moiety.